Nasdaq warns MaxCyte of listing-rule breach after 30-day sub-$1 bid price streak

Reuters
Mar 21
Nasdaq warns MaxCyte of listing-rule breach after 30-day sub-$1 bid price streak
  • MaxCyte received a Nasdaq notice stating it is not in compliance with Listing Rule 5450(a)(1) after its stock closed below $1.00 for 30 consecutive trading days.
  • The company has 180 calendar days, until September 14, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days.
  • If compliance is not regained by that deadline, MaxCyte may seek an additional 180-day period by applying to transfer its listing to the Nasdaq Capital Market.
  • Nasdaq could move to delist the shares if MaxCyte is deemed unable to cure the deficiency, though the company would have the right to appeal.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-032761), on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10